Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aspire Biopharma Holdings Inc (ASBP)

Aspire Biopharma Holdings Inc (ASBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,210
  • Shares Outstanding, K 107,477
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,540 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.86
  • Price/Sales 2,423.99
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.50
  • Most Recent Earnings $-0.04 on 11/14/25
  • Next Earnings Date 04/06/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0709 +50.49%
on 12/10/25
0.1242 -14.09%
on 11/18/25
+0.0004 (+0.38%)
since 11/14/25
3-Month
0.0709 +50.49%
on 12/10/25
0.4691 -77.25%
on 10/30/25
-0.3052 (-74.10%)
since 09/15/25
52-Week
0.0709 +50.49%
on 12/10/25
15.8000 -99.32%
on 02/12/25
-11.3233 (-99.07%)
since 12/12/24

Most Recent Stories

More News
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, received...

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Provides Q3 2025 Business Update

ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today...

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology,...

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, has...

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today...

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology,...

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

BUZZ BOMBâ„¢ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)
Aspire Biopharma Holdings, Inc. Announces CEO Transition

Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO

ASBPW : 0.0300 (+9.09%)
ASBP : 0.1080 (+13.68%)

Business Summary

Aspire Biopharma Inc. is a privately held, early-stage biopharmaceutical technology company. It engaged in the business of developing and marketing a disruptive technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals and supplements. Aspire Biopharma Inc., formerly known as PowerUp...

See More

Key Turning Points

3rd Resistance Point 0.1313
2nd Resistance Point 0.1229
1st Resistance Point 0.1089
Last Price 0.1080
1st Support Level 0.0865
2nd Support Level 0.0781
3rd Support Level 0.0641

See More

52-Week High 15.8000
Fibonacci 61.8% 9.7915
Fibonacci 50% 7.9355
Fibonacci 38.2% 6.0794
Last Price 0.1080
52-Week Low 0.0709

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar